EBITDA Margin % is calculated as EBITDA divided by its Revenue. MindWalk Holdings's EBITDA for the
three
months ended in Jan. 2026 was $-2.71 Mil. MindWalk Holdings's Revenue for the
three
months ended in Jan. 2026 was $3.02 Mil. Therefore, MindWalk Holdings's EBITDA margin for the quarter that ended in Jan. 2026 was -89.73%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MindWalk Holdings EBITDA Margin % Related Terms
MindWalk Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MindWalk Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HYFT vs GANX, EXOZ, ANVS: EBITDA Margin % Comparison
For the Biotechnology subindustry, MindWalk Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a EBITDA Margin % of -89.73% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MindWalk Holdings and its competitors. According to the industry distribution chart, MindWalk Holdings ranks #417 out of 945 companies in the Biotechnology industry, placing it in the top 44.1%.
Is MindWalk Holdings' EBITDA Margin % too high?
MindWalk Holdings' current EBITDA Margin % is -89.73%. Based on the distribution chart, MindWalk Holdings ranks #417 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' EBITDA Margin % compare to GANX and EXOZ?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #417 out of 945 companies for EBITDA Margin %. This puts MindWalk Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MindWalk Holdings and its competitors. MindWalk Holdings's current EBITDA Margin % is -89.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.61, compared to a current price of $1.52 — trading 149.2% above its estimated fair value. The current EBITDA Margin % is -89.73%. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current EBITDA Margin % is -89.73% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.52 is trading 149.2% above its estimated GF Value™ of $0.61.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
EBITDA Margin %: -89.73%
GF Value™: $0.61 vs. price of $1.52 (149.2% above fair value)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score
Get the complete analysis for HYFT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
